News

GM-soy: A doubt  follows a yes
Enlarge image

Agri-biotechItalyGermanyEU

GM-soy: A doubt follows a yes

25.06.2012 - A European authority says Monsanto's roundup-ready soy is safe for man and environment. But there is doubt remaining.

Parma/Munich – For the first time, the European Food Safety Authority (EFSA) has approved the cultivation of genetically modified (GM) soy. So far, the  GM soy "roundup-ready" by US-industry leader Monsanto can only be imported to the EU. The Scientific Opinion published by the EFSA’s GMO panel now paves the way for EU Commissioner John Dalli. The Commission can give Monsanto the green light for cultivating the crop on European soils if the EU member states will not achieve a qualified majority on the issue.

However, there might be a fierce head wind blowing. German anti-GMO association Testbiotech e.V. points out that there's a legal minefield in the way. A study done on behalf of Testbiotech says that an expected admittance might violate EU law. Matter of concern: the EFSA opinion itself. According to the study, the EFSA should have also tested if the residues of pesticides to be used (in this case glyphosate) could have negative effects on human health. Not implementing this concern in the risk assessment could be equivalent to a breach of EU laws. The crop in question is soybean 40-3-2. It carries a gene that makes it tolerant to glyphosate (brand name: Roundup). That is why the soybean is also dubbed "roundup-ready soy". The EFSA opinion clearly regulates the use of this pesticide: "It should result in similar or reduced environmental impacts compared with conventional soybean cultivation." The panel also recommends that case-specific monitoring of (1) changes in weed community diversity; and (2) the evolution of resistance to glyphosate in weeds should be deployed.

http://www.european-biotechnology-news.com/news/news/2012-02/gm-soy-a-doubt-follows-a-yes.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC5.41 EUR4.04%
  • WILEX5.25 EUR3.35%
  • BIOFRONTERA2.34 EUR1.74%

FLOP

  • VITA 345.86 EUR-6.69%
  • FORMYCON26.31 EUR-6.04%
  • MORPHOSYS63.42 EUR-6.02%

TOP

  • 4SC5.41 EUR322.7%
  • WILEX5.25 EUR83.6%
  • PAION2.85 EUR21.3%

FLOP

  • BIOTEST72.00 EUR-25.9%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.16 EUR-17.6%

TOP

  • SANTHERA96.00 CHF2361.5%
  • CYTOS1.27 CHF647.1%
  • WILEX5.25 EUR517.6%

FLOP

  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.34 EUR-26.6%

No liability assumed, Date: 05.05.2015